Peptilogics raises $78M in Series B2 funding. Peptilogics, a Pittsburgh, PA-based clinical-stage biotechnology company developing surgical therapeutics to effectively treat and prevent serious medical device infections, closed a $78m Series B2 financing round. Presight Capital, Thiel Bio, and Founders Fund led the round, with participation from new investors AMR Action Fund, Narya Capital, and Beyond Ventures. This brings Peptilogics' total equity funding to approximately $120m, along with substantial grant support from CARB-X. The company intends to use the funds to conduct the Phase 2/3 pivotal trial of zaloganan (PLG0206), an investigational treatment for prosthetic joint infections (PJI). Led by CEO Jonathan Steckbeck, PhD., and COO Nick Pachuda, Peptilogics is developing therapeutics for orthopedic hardware-related infections. The company's lead candidate, zaloganan (PLG0206), is an investigational treatment for prosthetic joint infections currently in clinical development. In Peptilogics' Phase 1b study, zaloganan irrigation administered during DAIR procedures resulted in 13 of 14 patients (93%) remaining infection-free at 12 months.

Peptilogics has raised $78 million in a Series B2 financing round to advance its investigational treatment, zaloganan (PLG0206), into a Phase 2/3 pivotal trial for prosthetic joint infections (PJI). The round was led by Presight Capital, Thiel Bio, and Founders Fund, with new investors including AMR Action Fund, Narya Capital, and Beyond Ventures. This brings Peptilogics' total equity funding to approximately $120 million.